A $300,000 investment split equally among Duke Energy, Philip Morris, and Johnson & Johnson generates about $8,590 in annual passive income with a blended yield of 2.86%. Duke Energy offers the highest yield at 3.39%, followed closely by Philip Morris at 3.30%, and Johnson & Johnson at 1.90%. These companies have a strong track record of raising dividends and provide reliable quarterly income, making them attractive for retirees seeking steady cash flow without selling shares. The portfolio balances regulated utility, tobacco, and healthcare sectors, offering diversified income sources with growth potential.
Johnson & Johnson trades at USD 280.83 with a 1-day change of -0.45% as of Nov 10, 2026 22:32 WIB on Pluang. Philip Morris shows a positive 0.86% change, priced at USD 194.78, while Duke Energy is slightly down 0.20% at USD 127.84. Dividend yields on Pluang align closely with the article, with Duke Energy at 3.39% and Philip Morris at 3.31%.
Johnson & Johnson announced that CAPLYTA (lumateperone) met primary and key secondary endpoints in a Phase 3 study for treating manic episodes in bipolar I disorder, showing significant symptom improvement as early as Day 3 and sustained through Week...
Following the 2026 midterm elections resulting in a divided U.S. government, four dividend-paying blue-chip stocks—Duke Energy, Procter & Gamble, Johnson & Johnson, and JPMorgan Chase—are highlighted for their resilience amid legislative gridlock. Th...
Johnson & Johnson announced promising Phase 1 results for a novel immunotherapy combining pasritamig and JNJ-9401, targeting two prostate cancer proteins to activate T cells. In the trial, 73% of patients saw PSA levels drop by at least 50%, with nea...
Three dividend stocks from healthcare, real estate, and energy sectors—Johnson & Johnson, Realty Income, and Chevron—stand out for their reliable dividends supported by strong cash flow and manageable debt. Johnson & Johnson boasts 64 years of consec...
Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more ...
